Lv1
40 积分 2021-08-19 加入
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
2天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
3天前
已完结
Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts
3天前
已完结
Flare-up phenomenon or pseudoprogression after CAR T-cell infusion in non-Hodgkin aggressive lymphomas
4天前
已完结
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee
4天前
已完结
IL2-independent expansion, persistence, and antitumor activity in TIL expressing regulatable membrane-bound IL15
5天前
已完结
Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificity
8天前
已完结
The Unique Symptom Burden of Patients Receiving CAR T-Cell Therapy
12天前
已完结
Tumor burden quantified by Soluble B-Cell Maturation Antigen and Metabolic Tumor Volume determine myeloma CAR-T outcomes
20天前
已完结
Fulzerasib: First Approval
26天前
已完结
皖公网安备34019202002308
